This Article Full Text (PDF) All Versions of this Article: 1078155208096111v1 15/1/29    most recent References Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Chew, L. Articles by Chuen, V. S. L. Search for Related Content PubMed PubMed Citation Articles by Chew, L. Articles by Chuen, V. S. L. Social Bookmarking                         What's this?

Cutaneous reaction associated with weekly docetaxel administration

National Cancer Centre Singapore, National University of Singapore, 11 Hospital Drive, Singapore 169610, phmcst{at}nccs.com.sg

Vivianne Shih Lee Chuen, BSc Pharm Hon BCPS BCOP

National Cancer Centre Singapore, National University of Singapore, 11 Hospital Drive, Singapore 169610

Background. Docetaxel-based chemotherapy will remain clinically relevant and many of our patients will continue to receive the drug. In a recent phase 2 study of docetaxel 35 mg/m2 (weekly) in patients with metastatic breast cancer, the incidence of grade 3 cutaneous toxicity is 19%. The skin toxicity observed consists of limb/palmar-plantar erythematous reactions, or fixed-plaque erythrodysesthesia. Case series or reports have reported varied manifestations of skin reactions and include erythema multiforme, nail changes (onycholysis, pigmentation, paronychia), scleroderma, supravenous discoloration, radiation recall dermatitis, and flagellate erythema.

Method. We would like to report four patients with cutaneous reactions resulting from weekly administration of docetaxel.

Results. All cases are heavily pre-treated patients, receiving docetaxel as second or third line therapy. The cutaneous reactions occur at cycle 5. The time between chemotherapy to development of skin lesions is from 1 to 7 days. Lesions usually resolve with desquamation leaving behind areas with hyper-pigmentation or hypo-pigmentation over a period of 2 to 3 weeks. The management strategies include hand elevation, warm or cold compresses, topical and/or systemic antibiotics, topical and/or systemic corticosteroids, and cessation of drug.

Conclusions. There is a need for a systematic approach to manage these cutaneous reactions. Oncology trained pharmacists play vital roles in assessing, managing, documenting and patient education. J Oncol Pharm Practice (2009) 15: 29—34.

Key Words: Docetaxel • cutaneous reaction • skin toxicity

This version was published on March 1, 2009

Journal of Oncology Pharmacy Practice, Vol. 15, No. 1, 29-34 (2009)
DOI: 10.1177/1078155208096111


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?